mySELF
Autoimmune disease target discovery — Immunogenic and tolerogenic self-antigen prediction
mySELF offers accurate prediction of immunogenic and tolerogenic self-antigens. It is an autoimmune-focused adaptation of our best-in-class immunogenicity prediction engine, designed to quantify the immunogenic potential of self-derived peptides across both CD8 and CD4 contexts. It enables rational prioritization of pathogenic candidates and supports region-level selection for tolerance-oriented strategies by moving beyond MHC-binding and integrating presentation as well as T-cell activation features into a unified scoring framework.
What mySELF delivers
We offer large-scale patient cohort analyses with an average turnaround time of 2–3 months:
- Epitope prioritization: robust CD8 epitope prioritization for pathogenic mechanism and target discovery
- CD4 region assessment: region-based CD4 analysis aligned with tolerance-oriented concepts
- Final epitope selection: rational narrowing of large autoimmune candidate spaces
- Data integration: integration with HLA, expression, immunopeptidomics, and TCR datasets
Frequently asked questions about mySELF
What is mySELF?
mySELF predicts immunogenic and tolerogenic self-antigens. It adapts myNEO’s immunogenicity prediction engine for autoimmune disease, spanning CD8 and CD4 contexts.
Who uses mySELF?
mySELF supports teams working on autoimmune target discovery and tolerance-oriented strategies who need rational prioritization of pathogenic self-antigen candidates.
What is the typical turnaround for mySELF?
Large-scale patient cohort analyses with mySELF have an average turnaround time of 2–3 months.
Ready to use mySELF?
Talk to our team about integrating mySELF into your discovery or development workflow.